Related Experiment Videos
Genomic organization of human JAK2 and mutation analysis of its JH2-domain in leukemia
1Center for Human Genetics and Flanders Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium.
Abstract:
The Janus kinase family of proteins, with four mammalian members (JAK1, JAK2, JAK3 and TYK2), plays an essential role in the signal transduction pathway from non-catalytic cytokine receptors to the nucleus. We recently reported the involvement of ETV6-JAK2 fusion genes in the development of leukemia of both lymphoid and myeloid origin. Dominant missense mutations of hopscotch, a Drosophila JAK homologue, causing leukemia-like defects were described. One of these mutations affected a conserved residue of the kinase- like JH2 domain and the introduction of this mutation in murine Jak2 resulted in the constitutional activation of its kinase activity. In order to further analyze its role in leukemogenesis, we cloned human JAK2 and determined its genomic organization. Twenty-four exons spanning a region of approximately 150 kb were identified. A mutation analysis of the exons 13 to 19, encoding the kinase-like JH2 domain failed to detect activating mutations in leukemia samples, suggesting that this is a rare event in human leukemia.
Insights
Activating mutations in the Janus kinase 2 (JAK2) gene are rare in human leukemia. Researchers analyzed JAK2's genomic organization and found no activating mutations in the kinase-like JH2 domain in leukemia samples.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- The Janus kinase (JAK) family, including JAK1, JAK2, JAK3, and TYK2, is crucial for cytokine receptor signaling to the nucleus.
- ETV6-JAK2 fusion genes have been implicated in lymphoid and myeloid leukemias.
- Mutations in Drosophila JAK homologues (hopscotch) can cause leukemia-like defects, with one affecting the JH2 domain leading to constitutive kinase activation.
Purpose of the Study:
- To investigate the role of human JAK2 in leukemogenesis.
- To determine the genomic organization of human JAK2.
- To analyze for activating mutations in the JAK2 JH2 domain in leukemia samples.
Main Methods:
- Cloning and genomic organization determination of human JAK2.
- Mutation analysis of exons 13-19, encoding the kinase-like JH2 domain.
- Analysis of leukemia samples.
Main Results:
- Human JAK2 consists of 24 exons spanning approximately 150 kb.
- No activating mutations were detected in exons 13-19 of JAK2 in the analyzed leukemia samples.
- The study suggests activating mutations in the JAK2 JH2 domain are infrequent in human leukemia.
Conclusions:
- The genomic organization of human JAK2 has been elucidated.
- Activating mutations within the JAK2 JH2 domain appear to be a rare event in human leukemogenesis.
- Further research may be needed to explore other potential roles of JAK2 in leukemia development.